SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Casey JL, King DHJ, Chaplin LC, Haines AMR, Pedley RB, Mountain V, et al. Preparation, characterisation ant tumor targeting of cross-linked divalent and tri-valent anti-tumor Fab′ fragments. Br J Cancer 1996; 74: 13971405.
  • 2
    Pedley RB, Boden JA, Boden R, Dale R, Begent RHJ. Comparative radioimmunotherapy using intact or F(ab′)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br J Cancer 1993; 68: 6973.
  • 3
    Verhaar-Langereis MJ, Zonnenberg BA, de Klerk JMH, Blijham GH. Radioimmunodiagnosis and therapy. Cancer Treatment Rev 2000; 26: 310.
  • 4
    Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm 2000; 15: 1529.
  • 5
    Barendsen GW. Dose-fractionation, dose-rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 198197.
  • 6
    Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologout stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 33640.
  • 7
    Lane DM, Eagle KF, Begent RHJ, Hope-Stone LD, Green AJ, Casey JL, et al. Radioimmunotherapy of metastatic colorectal tumors with iodine-131–labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies. Br J Cancer 1994; 70: 5215.
  • 8
    Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996; 41: 187184.
  • 9
    Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys 1990; 18: 12619.
  • 10
    Bardies, M, Chatal, J-F. Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres. Phys Med Biol 1994;39: 96181.
  • 11
    O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36: 19029.
  • 12
    Flynn AA, Green AJ, Boxer GM, Casey JL, Pedley RB, Begent RHJ. A novel technique, using radioluminography, for the measurement of uniformity of radiolabeled antibody distribution in a colorectal cancer xenograft model. Int J Radiat Oncol Biol Phys 1999; 43: 1839.
  • 13
    Travis EL, Tucker SL. Iso-effect models and fractionated radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13: 2837.
  • 14
    Chester KA, Begent RHJ, Robson L, Keep P, Pedley RB, Boden JA, et al. Phage libraries for generation of clinically useful antibodies. Lancet 1994; 343: 4556.
  • 15
    Schultes BC, Zhang CS, Xue LY, Noujaim AA, Madiyalakan R. Immunotherapy of human ovarian carcinoma with OVARIX Mab-B43.13 in a human-PBL-SCID/BG mouse model. Hybridoma 1999;18: 4755.
  • 16
    Read DA, Cooper MS, Boden R, Boden JA, Chester KA, Begent RHJ. 99mTc labelling of MFE-23 (an anti-CEA single chain antibody) [abstract]. Br J Cancer 1997; 75(Suppl 1): 34.
  • 17
    Mayer A, Chester KA, Bhatia J, Pedley RB, Read DA, Boxer GM, et al. Exemplifying guidelines for preparation of recombinant DNA products in Phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody. Eur J Cancer 1998; 34: 96876.
  • 18
    Flynn AA, Green AJ, Boxer G, Pedley RB, Begent RHJ. A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumor morphology. Phys Med Biol 1999; 44: N151N159.
  • 19
    Flynn AA, Green AJ, Pedley RB, Boxer GM, Boden R, Begent RHJ. A mouse model for calculating the absorbed dose, from 131I and 90Y labelled antibodies, including a method for managing heterogeneity in kidney and tumor. Radiat Res 2001;156: 2835.
  • 20
    Flynn AA, Green AJ, Pedley RB, Boxer GM, Boden R, Bhatia J, et al. The effectiveness of radiolabelled antibodies for radioimmunotherapy in a colorectal xenograft model: a comparative study using the linear-quadratic formulation. Int J Radiat Biol 2001; 77: 50717.
  • 21
    Tannock IF. Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br J Radiol 1972; 45: 51524.
  • 22
    Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993; 34: 68994.
  • 23
    Muthaswamy MS, Roberson PL, Buchsbaum DJ. A mouse bone marrow dosimetry model. J Nucl Med 1998; 39: 12437.
  • 24
    Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 51528.
  • 25
    Howell RW, Goddu SM, Rao DV. Proliferation and the advantage of longer-lived radionuclides in radioimmunotherapy. Med Phys 1998; 25: 3742.
  • 26
    Thames HD, Withers HR, Peters LJ. Tissue repair capacity and repair kinetics deduced from multifractionated or continuous irradiation regimens with incomplete repair. Br J Cancer 1984; 49: 2639.
  • 27
    Dearling JLJ, Flynn AA, Pagoulatos C, Wilson GD, Woodcock M, Denholm E, et al. Influence of tumor cell response and nuclide selection on the efficacy of RIT [abstract]. Br J Cancer 2000; 83: 72.
  • 28
    Sharda, N, Yang C-R, Linsella T, Boothman D. Radiation resistance. In: Bertino JR. Encyclopedia of cancer. London: Academic Press, 1997: 140919.
  • 29
    Jones B, Dale, RG. Estimation of tumor hypoxic fraction from clinical data sets compatible with accelerated repopulation. Acta Oncol 1998;37: 2638.
  • 30
    Withers HR, McBride WH. Biologic basis of radiation therapy. In: Perez CA, Brady, LN. Principles and practice of radiation oncology. 3rd ed. Philadelphia: Lippincott-Raven, 1997: 79118.